Consensus LivaNova PLC Sao Paulo

Stocks

L2IV34

BRL2IVBDR007

Medical Equipment, Supplies & Distribution

Market Closed - Sao Paulo 14:37:37 2026-08-04 EDT			5-day change	1st Jan Change
54.50 ^BRL	+2.64%		-.--%	+24.71%

10-23	LivaNova PLC Announces Full 36-Month Core-VNS Results Demonstrating Sustained and Increasing Benefits of VNS Therapy for Drug-Resistant Epilepsy	CI
09-14	Livanova Insider Sold Shares Worth $273,032, According to a Recent SEC Filing	MT

019853aa.Z28iuhFsTG-9DaBCLE-Y2Icv0NCKE3l4jWKajKNH_BM.Ext77CkLHlzVaZgRfCH3nL8YpYG5Yygf3xvTz-F2y1oAWGHtfz0CWfxL4Q~ebba31a41cf89c245f6283b538b92cc4

Analysts' recommendations: LivaNova PLC

02-25	Needham Adjusts Price Target on LivaNova to $81 From $64	MT
12-19	KeyBanc Initiates LivaNova at Overweight With $81 Price Target	MT
25-10-01	LivaNova Shares Fall After Goldman Sachs Downgrade	MT
25-10-01	Goldman Sachs Downgrades LivaNova to Neutral From Buy, Trims Price Target to $55 From $56	MT
25-08-06	LivaNova beats estimates for Q2 revenue, raises FY guidance	RE
25-05-20	Wolfe Upgrades LivaNova to Outperform From Peer Perform, Price Target is $60	MT
25-02-26	Wolfe Research Downgrades LivaNova to Peer Perform From Outperform	MT
24-09-17	Baird Upgrades LivaNova to Outperform From Neutral	MT
24-07-31	Needham Raises LivaNova's Price Target to $75 From $72, Buy Rating Maintained	MT
24-02-27	Barclays Adjusts Price Target on LivaNova to $61 From $57, Keeps Equalweight Rating	MT
24-02-26	Barclays Raises Price Target on LivaNova to $61 From $57, Maintains Equalweight Rating	MT
24-02-22	Baird Adjusts LivaNova's Price Target to $62 From $56, Keeps Neutral Rating	MT
24-02-22	Wolfe Research Adjusts LivaNova's Price Target to $65 From $58, Keeps Outperform Rating	MT
24-02-22	Mizuho Securities Adjusts Price Target on LivaNova to $75 From $70, Maintains Buy Rating	MT
24-02-21	Needham Adjusts Price Target on LivaNova to $72 From $62, Keeps Buy Rating	MT
24-02-20	Mizuho Securities Upgrades LivaNova to Buy From Neutral, Raises Price Target to $70 From $60	MT
23-10-23	Needham Adjusts LivaNova Price Target to $62 From $71, Maintains Buy Rating	MT
23-09-06	HSBC Initiates LivaNova With Hold Rating, Price Target is $52	MT
23-05-08	Barclays Adjusts Price Target on LivaNova to $51 From $45, Maintains Equalweight Rating	MT
23-05-03	Needham Adjusts LivaNova's Price Target to $63 From $77, Keeps Buy Rating	MT
23-04-14	Mizuho Initiates LivaNova at Neutral With $48 Price Target	MT
22-12-21	Barclays Initiates Coverage on LivaNova With Equal Weight Rating, $62 Price Target	MT
22-11-23	Goldman Sachs Adjusts LivaNova's Price Target to $63 From $73, Keeps Buy Rating	MT
22-11-03	Needham Adjusts Price Target on LivaNova to $77 From $88, Maintains Buy Rating	MT
22-08-16	Goldman Sachs Cuts Price Target on LivaNova to $73 From $85, Maintains Buy Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
LIVANOVA PLC	-	-	-	-
ABBOTT LABORATORIES				+14.29%
STRYKER CORPORATION				+18.06%
MEDTRONIC PLC				+9.65%
ESSILORLUXOTTICA				+19.16%
CENCORA, INC.				+11.51%
HOYA CORPORATION				+17.34%
BECTON, DICKINSON AND COMPANY				-1.68%
IDEXX LABORATORIES, INC.				+24.56%
ALCON INC.				+29.2%
Average				+15.79%
Weighted average by Cap.				+14.88%